Brickell Biotech Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 13, 2021 16:01 ET | Source: Brickell Biotech, Inc. Brickell Biotech, Inc. Boulder, Colorado, UNITED STATES
Completed enrollment in Phase 3 pivotal Cardigan I study and exceeded 70% enrollment in Phase 3 pivotal Cardigan II study
- - -
- - -
Presented results from Phase 3 open-label, long-term safety study of sofpironium bromide gel, 5% & 15% at AAD VMX 2021
BOULDER, Colo., May 13, 2021 (GLOBE NEWSWIRE) Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced financial results for the first quarter ended March 31, 2021 and provided a corporate update.
Reports Further Characterize COVID Vaccine Skin Reactions
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Tofacitinib: Big Cutaneous Sarcoidosis Response in Small Study
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Amgen today announced that the U.S. Food and Drug Administration has accepted for review the supplemental New Drug Application for Otezla ® for the treatment of adults with mild-to-moderate plaque psoriasis who are candidates for phototherapy or systemic therapy. The FDA has set a Prescription Drug User Fee Act action date of December 19, 2021 . “Otezla has been prescribed to hundreds of thousands of patients with …
– Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for Otezla ® (apremilast) for the treatment of adults with mild-to-moderate plaque psoriasis who are candidates for phototherapy or systemic therapy. The FDA has set a Prescription Drug User Fee Act (PDUFA) action date of December 19, 2021 .